Itezocabtagene autoleucel

N/A

Report date: 2024/01/03 13:58:01

Base Information

Drug NameItezocabtagene autoleucel
Drug Alias NameCD30 CAR-T cell therapy (Tessa Therapeutics)TT-11TT11
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector > MMLV vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitors
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTessa Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTessa Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, Anaplastic +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A